BellaSeno Successfully Completes Two Clinical Trials with Novel, Resorbable Breast Implants
January 14, 2025 04:00 ET
|
AKAMPION
One-year follow-up data confirm favorable safety profile of BellaSeno´s scaffolds compared to silicone implantsCompany plans expansion to primary breast augmentation and lumpectomy Leipzig, Germany/...
Prodeon Medical Announces Enrollment Completion for Expander-2 Pivotal Trial
January 13, 2025 08:00 ET
|
Prodeon Medical
Prodeon Medical completes patient enrollment for the Expander-2 Trial, a study evaluating the Urocross Expander System for LUTS due to BPH.
Abivax Achieves Key Milestone in Phase 3 ABTECT Trial Enrollment
January 09, 2025 11:35 ET
|
Abivax
Abivax Achieves Key Milestone in Phase 3 ABTECT Trial Enrollment Phase 3 ABTECT Trial evaluating obefazimod for moderately to severely active ulcerative colitis (“UC”) reaches 1,003 of 1,224...
RQ Bio welcomes positive CHMP opinion on Kavigale for prevention of COVID-19 in immunocompromised individuals
January 09, 2025 05:00 ET
|
RQ Biotechnology
RQ Bio welcomes positive CHMP opinion on Kavigale for prevention of COVID-19 in immunocompromised individuals
ViGeneron Announces FDA Rare Pediatric Disease Designation for VG901 and DSMB Approval to Advance Dose Escalation in Phase 1b Retinitis Pigmentosa Trial
January 08, 2025 08:00 ET
|
ViGeneron GmbH
VG901 is the first-in-class and only clinical-stage therapy designed to deliver the functional CNGA1 gene intravitreally (IVT) to target retinal photoreceptor cells in patients with retinitis...
tiakis Biotech AG Receives Positive Scientific Advice from the U.S. FDA for Planned Phase II Trial of Tiprelestat
January 08, 2025 04:00 ET
|
AKAMPION
- tiakis and Stanford University are preparing for a Phase II in Pulmonary Arterial Hypertension (PAH) Kiel, Germany, January 8, 2025 – tiakis Biotech AG, a clinical-stage biopharmaceutical company...
CytoMed Therapeutics signs Business & Research Collaboration Agreement with India’s SunAct Cancer Institute Private Limited to advance use of allogeneic off-the-shelf Gamma Delta T Cells for treatment of solid cancers in a proposed Phase 2 clinical trial in India
January 06, 2025 07:00 ET
|
CYTOMED THERAPEUTICS LIMITED
SINGAPORE, Jan. 06, 2025 (GLOBE NEWSWIRE) -- CytoMed Therapeutics Limited (NASDAQ: GDTC) (“CytoMed” or “Company”), a Singapore-based clinical stage biopharmaceutical company focused on harnessing...
InflaRx Announces First Patient Dosed in Phase 2a Study for Oral C5aR Inhibitor INF904
December 20, 2024 07:30 ET
|
InflaRx N.V.
JENA, Germany, Dec. 20, 2024 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics targeting the complement system, today...
Remedy Plan Therapeutics Initiates Dosing in Phase 1 Clinical Trial of RPT1G, a First-In-Class Hyperbolic NAMPT Inhibitor
December 18, 2024 08:30 ET
|
Remedy Plan Therapeutics
Remedy Plan Therapeutics Initiates Dosing in Phase 1 Clinical Trial of RPT1G, a First-In-Class Hyperbolic NAMPT Inhibitor
YPrime Commits to United Nations Global Compact, Pledging to Align its Sustainable Business Practices with UN Goals
December 17, 2024 09:57 ET
|
Y-Prime, LLC
YPrime pledges to United Nations Global Compact, expanding its program of sustainable business practices.